lifestyle.travelshq.com

Author: Compass Therapeutics

Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer

April 27, 2026
Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer

April 24, 2026
Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update

March 5, 2026